L. S. Smith, M. Nelson, S. Naik and J. Woten, “Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C,” The Annals of Pharmacotherapy, Vol. 45, No. 5, 2011, pp. 639-648. doi:10.1345/aph.1P430

has been cited by the following article:

• TITLE: Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen

  AUTHORS: David C. Pryde, Thien-Duc Tran, Mark Gardner, Chris Pickford, Stephen M. Shaw, Mike Westby, Tanya Parkinson, Caroline Smith-Burchnell, Rob Webster, Satish Dayal

  KEYWORDS: HCV; Replicon; Antiviral; Cell-Based Screen

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.3 No.1, March 29, 2013

  ABSTRACT: A high throughput screen of the Pfizer compound collection was carried out using a hepatitis C virus (HCV) genotype 1b subgenomic replicon cell line. Those confirmed hits that demonstrated broad spectrum activity without overt cytotoxicity were further evaluated, leading to the identification of a series of pyrrolopyridines with excellent antiviral activity in a fully infectious HCV cell-based assay and pharmacokinetic properties.